Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
3.770
-0.030 (-0.79%)
At close: Dec 5, 2025, 4:00 PM EST
3.610
-0.160 (-4.24%)
After-hours: Dec 5, 2025, 5:01 PM EST
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2024. The number of employees decreased by 9 or -45.00% compared to the previous year.
Employees
11
Change (1Y)
-9
Growth (1Y)
-45.00%
Revenue / Employee
n/a
Profits / Employee
-$1,713,744
Market Cap
15.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLRB News
- 22 days ago - Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research - GlobeNewsWire
- 3 months ago - Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 - GlobeNewsWire
- 3 months ago - Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit - GlobeNewsWire
- 3 months ago - Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September - GlobeNewsWire
- 3 months ago - Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research - GlobeNewsWire
- 3 months ago - Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer - GlobeNewsWire